Claude Gimmi at Boehringer to present at Oncology Partnering Conference – Feb 27-28, 2012, Las Vegas

Printer-friendly versionPDF version

Claude Gimmi, Global Head, Business Development & Licensing Oncology, Therapeutic Alliances & Strategic Partnerships at Boehringer-Ingelheim to give a Featured Presentation at the Oncology Partnering and Deal-making Conference (February 27-28, 2012 in Las Vegas, NV)

(PressReleasePoint) -Claude Gimmi, Global Head, Business development and Licensing Oncology, Therapeutic Alliances and Strategic Partnerships at Boehringer-Ingelheim to give a Featured Presentation on “Sincerely, Yours – Partnering with Boehringer Ingelheim in Oncology” at the Oncology Partnering and Deal-making Conference to be held on February 27-28, 2012 in Las Vegas, NV by GTC.

Sincerely, Yours – Partnering with Boehringer Ingelheim in Oncology
 
The presentation will outline Boehringer Ingelheim’s Oncology partnering strategy. The primary focus for Oncology will be on programs and collaborations which fit into the current and emerging scientific focus areas where additional knowhow will support and accelerate internal development with focus on early programs from lead optimization to end of phase I. In this specific focus area, Boehringer Ingelheim is interested in compounds with a novel mode of action and a sound scientific rationale of differentiated compounds compared to current standards of care. In addition to the level of scientific and medical innovation, the overall attractiveness of a licensing candidate would clearly benefit from a combination with suitable predictive biomarkers and preclinical models.
 
The author will address the following key questions:
• Why does the Oncology market represent an attractive investment opportunity for Pharma?
• What are the key unmet medical needs and research and development focus area at Boeringer Ingelheim?
• What kind of partnering opportunities in Oncology is Boehringer Ingelheim interested in?

Dr. Gimmi acts as Head of Global Business Development and Licensing Oncology at Boehringer Ingelheim. She leads the cross-functional Oncology Advisory Team responsible for global licensing activities in the therapeutic area Oncology. She received her MD degree and her PhD in tumor immunology form the University of Bern (Switzerland), and completed a postdoctoral fellowship in tumor immunolog at the Dana-Farber Cancer Institute, Harvard Medical School in Boston where she was promoted to an instructor. After a few years as an assistant professor in Oncology at the University of Bern, Dr. Gimmi joined Roche in the role of a translational medicine leader with the responsibility of clinical lead for research, in-licensing and clinical development in Oncology.  She joined Boehringer Ingelheim’s International Business Development and Licensing organization in 2011. Her current focus is on licensing projects in the area of early drug development in Oncology with special focus on scientific and medical innovative compounds and programs with clear predictive biomarkers for personalized medicine.
 
 
The Oncology Partnering & Deal Making Conference is a partnering and business development conference that gives global biotechnology and pharmaceutical companies an opportunity to network with high-level executives from top pharma and various biotech/pharmaceutical companies, as well as explore potential collaborations, and learn about relevant issues in Oncology and partnerships that will affect the industry. This event also provides a unique venue for attendees to learn about Oncology business development trends, market, and novel technologies that shape up the industry. 

The top companies and experts in the Oncology field will come together to discuss the latest discoveries, technologies and partnership opportunities from their organization. Companies include Array Biopharma, A&G Pharmaceutical, Amgen, Astellas Pharma, Aveo ­­­­­­Pharmaceuticals, Boehringer Ingelheim, Eisai , Eli Lilly, Endocyte, Epizyme, Epic Sciences, Micromet, Novartis, OncoMed, Pfizer , Plexxikon , Pullan Consulting, QIAGEN, SAIC-Frederick, Seattle Genetics, Third Rock Ventures, YM Biosciences, and many more!
 

The conference is part of the Targets and Strategies in Drug Discovery Summit, which consists of 4 tracks including the 2nd Ubiquitin Research and Drug Discovery , 4th Ocular Diseases & Drug Discovery , and 3rd Cancer Targets and Therapeutics Conference.


For more information, please visit www.gtcbio.com